Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silo Pharma (SILO) Liabilities and Shareholders Equity (2019 - 2025)

Silo Pharma (SILO) has disclosed Liabilities and Shareholders Equity for 7 consecutive years, with $7.6 million as the latest value for Q4 2025.

  • Quarterly Liabilities and Shareholders Equity rose 2.61% to $7.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $26.5 million through Dec 2025, down 14.26% year-over-year, with the annual reading at $7.6 million for FY2025, 2.61% up from the prior year.
  • Liabilities and Shareholders Equity hit $7.6 million in Q4 2025 for Silo Pharma, up from $6.4 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $13.0 million in Q3 2022 to a low of $5.0 million in Q2 2021.
  • Historically, Liabilities and Shareholders Equity has averaged $8.6 million across 5 years, with a median of $8.3 million in 2024.
  • Biggest five-year swings in Liabilities and Shareholders Equity: soared 1262.3% in 2021 and later crashed 37.03% in 2024.
  • Year by year, Liabilities and Shareholders Equity stood at $10.5 million in 2021, then rose by 10.99% to $11.6 million in 2022, then tumbled by 33.47% to $7.7 million in 2023, then decreased by 4.32% to $7.4 million in 2024, then increased by 2.61% to $7.6 million in 2025.
  • Business Quant data shows Liabilities and Shareholders Equity for SILO at $7.6 million in Q4 2025, $6.4 million in Q3 2025, and $6.7 million in Q2 2025.